EXOZ

Business Context and Reporting Period

Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: eXoZymes is a pre-revenue biotechnology company developing a synthetic biology platform for cell-free, multi-step enzyme-based systems to produce pharmaceuticals, fuels, and materials. The company completed its IPO in November 2024. As of June 30, 2025, it operates as a single reportable segment and is classified as an Emerging Growth Company and Smaller Reporting Company.

Key Financial Metrics

Note: The company has no debt obligations other than lease liabilities. Interest income of $170,864 was recognized for the six months ended June 30, 2025, compared to interest expense of $(29,782) in the prior year period.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by 78.0% to $4.22 million for the six months ended June 30, 2025, compared to $2.37 million in the prior year period. This was driven by a 92.5% increase in total operating costs.
• Expense Growth:
  • General & Administrative (G&A): Increased 71.3% to $3.12 million, primarily due to higher compensation (new hires not covered by grants), professional fees, and D&O insurance costs.
  • Research & Development (R&D): Increased 167.6% to $1.38 million (net of grants). This increase is attributed to new hires, higher salaries, stock-based compensation, and a reduction in grant funding offsets.
• Cash Position: Cash and cash equivalents decreased by $2.73 million (28.1%) from December 31, 2024, to June 30, 2025, reflecting the burn rate from operations. However, this represents a significant increase from the $158,239 cash balance in June 2024, following the November 2024 IPO.
• Grant Receivables: Decreased by 65.1% to $257,407 due to the completion of certain grants and timing of drawdowns.

Outlook, Risks, and Management Commentary

• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status. The company relies on securing additional financial support through equity/debt financing or profitable operations.
• Subsequent Events:
  • On July 1, 2025, the company was awarded a $3 million share of a $9.2 million grant from the U.S. National Science Foundation (NSF) for cell-free systems.
  • On July 25, 2025, shareholders approved the "2025 Equity Incentive Plan," adding 1,250,000 shares to the pool.
• Risk Factors:
  • Regulatory & Trade: Potential adverse effects from U.S. tariff changes, trade policy shifts, and restrictions on federal research grants.
  • Technology: Uncertainty regarding the commercial viability and regulatory approval of the company's synthetic biology platform.
  • Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, though remediation efforts are ongoing.
• Liquidity: With approximately $6.3 million in working capital as of June 30, 2025, management believes it has sufficient funds for near-term operations but may need to raise additional capital in the future.

Key Facts for Investor Verification

• Pre-Revenue Status: Verify the timeline for commercial product launch and revenue generation, as the company currently has $0 operating income.
• Burn Rate: Monitor the monthly cash burn rate (approx. $1.3 million for the six-month period) against the current cash balance of ~$7 million to assess runway.
• Grant Dependency: Assess the sustainability of operations given the reduction in grant funding offsets and the reliance on future government grants (e.g., the new NSF award).
• Internal Controls: Review the progress of remediation for the disclosed material weaknesses in internal controls over financial reporting.
• Dilution Risk: Note the recent approval of an additional 1.25 million shares for the equity incentive plan and the existence of ~2 million anti-dilutive securities (warrants, options, RSUs).